Ad-PANX1 injection inhibited hepatic glucose production, improved glucose intolerance, decreased fasting hyperglycemia (P < 0.05), and enhanced global insulin sensitivity in mice (Fig. 3a-d). The gene discussed is INS; the disease is Glucose intolerance.